In this edition:

• AFA Census closes on May 31
• Report adjoining hotel rooms on CrewCare
• FDA requires stronger warnings about rare but serious incidents related to sleep medications

AFA Census closes on May 31!

The Association of Flight Attendants-CWA 2019 Census is a project to better understand the demographic make-up of our union, including your aspirations, needs, and preferences. We also want to know in what areas of your community you may already be engaged in making a difference for you, your family, and the place where you live. All of this will help us build power together so we can continue to advance our Flight Attendant careers.

The University of New Hampshire Survey Center (UNHSC) is conducting this very important data gathering effort. You should have received emails and possibly a phone call to encourage you to complete the Census. You may have a pre-filled email from “Sara Nelson via UNH” with the subject line “AFA Census – Response Requested.”

Our contract with UNHSC ensures your information remains confidential within AFA. It does not allow UNHSC to share any of your information with outside organizations. A summary of the final results will be shared with AFA members.

The AFA census can be accessed using the following link: https://unh.az1.qualtrics.com/jfe/form/SV_9TguTDVCSOZJEmF.

Reminder: report adjoining hotel rooms on CrewCare

A message from your Hotel Committee

As previously published on April 9, your Hotel Committee needs your assistance in reporting instances of adjoining rooms with connecting doors assigned to crews on layovers.  If you are assigned an adjoining and connecting room, even if you are able to switch rooms, please make note of the hotel, room number and date and file a CrewCare report on the situation.

CrewCare reports are automatically routed to Alaska management, API (Accommodations Plus International, the company’s hotel contractor), and your AFA Hotel Committee Members.  Representatives from API and management use the data from the reports to follow up on each situation with the corresponding hotel.  CrewCare can be easily accessed from the Hotel, Travel, & Station menu of the inflight website or by using the CrewCare icon on the home screen of your IMD.

Management has asked that we report these situations each and every time that they occur.  The more information that we are able to provide, the more effectively each hotel can be held accountable.

FDA requires stronger warnings about rare but serious incidents related to sleep medications

A message from your Employee Assistance Program (EAP)/Professional Standards Committee

Updated warnings for eszopiclon (Lunesta) zaleplon (Sonata) and zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, and Zolpimist).

At the end of April 2019, The U.S. Food and Drug Administration announced that the agency’s most prominent warning will now be required on certain prescription insomnia drugs.  The warning follows FDA’s review of 66 cases of serious injuries and/or  deaths resulting from various complex sleep behaviors after taking these medicines. These complex sleep behaviors have included  falls, burns, near-drowning, exposure to extreme cold temperatures leading to loss of limb or near death, self-injuries such as gunshot wounds, carbon monoxide poisoning, fatal motor vehicle collisions with the patient driving and suicide. The new warnings will be required for eszopiclone (Lunesta), zaleplon (Sonata) and zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, and Zolpimist).

“While these incidents are rare, they are serious and it’s important that patients and health care professionals are aware of the risk. These incidents can occur after the first dose of these sleep medicines or after a longer period of treatment, and can occur in patients without any history of these behaviors and even at the lowest recommended doses,” said FDA Acting Commissioner Ned Sharpless, M.D.  In addition to the warning, the agency is requiring the addition of a contraindication to not use these medicines in patients who have experienced an episode of complex sleep behaviors after taking them. The warning and contraindication are intended to make the warning more prominent and reflect the risk of serious injury and death.